Growth Hormone Secretagogue Research: Complete Category Guide

<p>Growth hormone secretagogues (GHS) are a class of research compounds that stimulate GH release through one of two primary mechanisms: direct activation of the GH secretagogue receptor (GHSR-1a, the ghrelin receptor) or activation of the GHRH receptor on pituitary somatotrophs. Both pathways converge on increased GH secretion, but through distinct pharmacological mechanisms that make each class valuable for specific research questions.</p><h2>GHSR-1a Agonists (Ghrelin Receptor)</h2><h3>Ipamorelin</h3><p>The most selective GHSR-1a agonist in the research catalog. Minimal stimulation of cortisol, ACTH, or prolactin at research concentrations — making it the cleanest GHS research tool for studying isolated GH secretion via the ghrelin receptor pathway.</p><h2>GHRH Receptor Agonists</h2><h3>Sermorelin</h3><p>GHRH 1-29 analog. Short half-life (~10-20 minutes) produces acute pulsatile GH release model. Historically used as a diagnostic tool for GH deficiency in children (no longer available pharmaceutically).</p><h3>CJC-1295 (No DAC)</h3><p>Modified GHRH 1-29 with DPP-IV resistance. Half-life approximately 30 minutes. Best for pulsatile GH release research while providing greater metabolic stability than native GHRH.</p><h3>CJC-1295 (With DAC)</h3><p>Albumin-binding GHRH analog. Half-life approximately 7-10 days. Produces sustained GH release model — fundamentally different pharmacokinetics from short-acting GHRH analogs.</p><h3>Tesamorelin</h3><p>Full 44-amino acid GHRH sequence with N-terminal modification. FDA-approved for HIV lipodystrophy. Provides the most well-characterized GHRH-R agonism clinical reference dataset.</p><h2>IGF-1 Downstream</h2><h3>IGF-1 LR3</h3><p>Long-acting IGF-1 analog that bypasses GH axis stimulation to directly activate IGF-1R. Useful for studying downstream IGF-1 effects independently of GH release.</p><h2>Combination Research: Dual-Pathway Models</h2><p>CJC-1295 + ipamorelin is the most studied dual-pathway GH secretagogue combination in research settings. The complementary mechanism — GHRH-R activation (CJC-1295) + GHSR-1a activation (ipamorelin) — allows researchers to study additive GH release models. TX Research Peptides supplies a pre-formulated CJC-1295/Ipamorelin blend.</p><p>Q: What is the difference between GHRH-analogs and GHSR agonists?</p><p>A: GHRH analogs (CJC-1295, sermorelin, tesamorelin) activate the GHRH receptor on pituitary somatotrophs. GHSR agonists (ipamorelin, GHRP compounds) activate the ghrelin receptor. Both pathways drive GH secretion but through distinct molecular mechanisms.</p><p>Related: Ipamorelin → | CJC-1295/Ipamorelin Blend → | CJC-1295 No DAC → | Tesamorelin → | Sermorelin → | IGF-1 LR3 →</p>